Data generated by the rapidly evolving human biomonitoring (HBM) programmes are providing invaluable opportunities to support and advance regulatory risk assessment and management of chemicals in occupational and environmental health domains. However, heterogeneity across studies, in terms of design, terminology, biomarker nomenclature, and data formats, limits our capacity to compare and integrate data sets retrospectively (reuse). Registration of HBM studies is common for clinical trials; however, the study designs and resulting data collections cannot be traced easily. We argue that an HBM Global Registry Framework (HBM GRF) could be the solution to several of challenges hampering the (re)use of HBM (meta)data. The aim is to develop a global, host-independent HBM registry framework based on the use of harmonised open-access protocol templates from designing, undertaking of an HBM study to the use and possible reuse of the resulting HBM (meta)data. This framework should apply FAIR (Findable, Accessible, Interoperable and Reusable) principles as a core data management strategy to enable the (re)use of HBM (meta)data to its full potential through the data value chain. Moreover, we believe that implementation of FAIR principles is a fundamental enabler for digital transformation within environmental health. The HBM GRF would encompass internationally harmonised and agreed open access templates for HBM study protocols, structured web-based functionalities to deposit, find, and access harmonised protocols of HBM studies. Registration of HBM studies using the HBM GRF is anticipated to increase FAIRness of the resulting (meta)data. It is also considered that harmonisation of existing data sets could be performed retrospectively. As a consequence, data wrangling activities to make data ready for analysis will be minimised. In addition, this framework would enable the HBM (inter)national community to trace new HBM studies already in the planning phase and their results once finalised. The HBM GRF could also serve as a platform enhancing communication between scientists, risk assessors, and risk managers/policy makers. The planned European Partnership for the Assessment of Risk from Chemicals (PARC) work along these lines, based on the experience obtained in previous joint European initiatives. Therefore, PARC could very well bring a first demonstration of first essential functionalities within the development of the HBM GRF.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijheh.2021.113826 | DOI Listing |
Cureus
December 2024
Department of Obstetrics and Gynecology, Osaka Metropolitan University Graduate School of Medicine, Osaka, JPN.
Aim This study evaluates university students' knowledge and attitudes toward Human Papillomavirus (HPV) vaccination and cervical cancer screening and assesses the impact of educational interventions. Methods Participants from Osaka Metropolitan University, Osaka City University, and Osaka Prefecture University completed questionnaires before and after receiving educational materials, including cartoons and a video featuring medical professionals. We compared the correct answer rates for knowledge-related questions and evaluated changes in behavioral characteristics and attitudes toward HPV vaccination and cervical cancer screening before and after distributing the educational materials.
View Article and Find Full Text PDFBackground: The increased use of chemicals leads to a continuous deposition of chemicals in the environment and to a continuous increase in exposure of the global and the European population. Comprehensive burden of disease analyses are however still missing for many countries.
Methods: Using the World Health Organization's Environmental Burden of Disease (EBD) approach and combining data from the European Human Biomonitoring (HBM) dashboard with disease and population data, we estimated the comprehensive attributable burden (AB) for the year 2021, in the best-case quantified by disability-adjusted life years (DALY).
J Indian Soc Pedod Prev Dent
October 2024
Department of Pedodontics and Preventive Dentistry, Sardar Patel Post Graduate Institute of Dental and Medical Sciences, Lucknow, Uttar Pradesh, India.
Cancers (Basel)
December 2024
BC Cancer, Vancouver Center, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada.
Background/objectives: Pembrolizumab monotherapy is approved in Canada for first-line treatment of advanced NSCLC with PD-L1 ≥ 50% and no EGFR/ALK aberrations. However, approximately 55% of these patients do not respond to pembrolizumab, underscoring the need for the early intervention of non-responders to optimize treatment strategies. Distinguishing the 55% sub-cohort prior to treatment is a real-world dilemma.
View Article and Find Full Text PDFPLoS One
January 2025
SLIIT Business School, Sri Lanka Institute of Information Technology, Malabe, Sri Lanka.
This study explores the integration of sexual and reproductive health (SRH) education in Sri Lanka, utilizing the Health Belief Model (HBM) to predict the perceived quality of SRH education among non-state undergraduate students. In many Asian countries, including Sri Lanka, cultural resistance and skepticism often challenge SRH education initiatives. The research is based on a questionnaire survey, examining factors influencing the perceived quality of SRH education, such as cultural norms, embarrassment, attitudes, awareness, and institutional support.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!